NeuroPace Inc. (NPCE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Nelson Cox - Lake Street Ross Osborn - Cantor Fitzgerald Priya Sachdev - UBS Rohin Patel - JPMorgan Michael Polark - Wolfe Research Operator Greetings and welcome to the NeuroPace First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago.
Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, NeuroPace (NPCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
NeuroPace (NPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.5% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes NeuroPace (NPCE) a New Buy Stock
NeuroPace (NPCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
